Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment

M. Fioramonti, V. Fausti, F. Pantano, M. Iuliani, G. Ribelli, F. Lotti, Y. Pignochino, G. Grignani, D. Santini, G. Tonini, B. Vincenzi

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to standard treatments, therefore novel therapies are needed. c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. The present study aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ in in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signaling pathways. Furthermore, CBZ leads to the inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor κB (RANK), due to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.

Original languageEnglish
Article number4177
JournalScientific Reports
Volume8
Issue number1
DOIs
Publication statusPublished - Dec 1 2018

Fingerprint

Osteosarcoma
Bone and Bones
Growth
Neoplasms
cabozantinib
RANK Ligand
Cellular Microenvironment
Osteoprotegerin
Tumor Microenvironment
Receptor Protein-Tyrosine Kinases
Cytoplasmic and Nuclear Receptors
Coculture Techniques
Osteoblasts
Oncogenes
Cell Movement
Cell Proliferation

ASJC Scopus subject areas

  • General

Cite this

Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. / Fioramonti, M.; Fausti, V.; Pantano, F.; Iuliani, M.; Ribelli, G.; Lotti, F.; Pignochino, Y.; Grignani, G.; Santini, D.; Tonini, G.; Vincenzi, B.

In: Scientific Reports, Vol. 8, No. 1, 4177, 01.12.2018.

Research output: Contribution to journalArticle

Fioramonti, M, Fausti, V, Pantano, F, Iuliani, M, Ribelli, G, Lotti, F, Pignochino, Y, Grignani, G, Santini, D, Tonini, G & Vincenzi, B 2018, 'Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment', Scientific Reports, vol. 8, no. 1, 4177. https://doi.org/10.1038/s41598-018-22469-5
Fioramonti, M. ; Fausti, V. ; Pantano, F. ; Iuliani, M. ; Ribelli, G. ; Lotti, F. ; Pignochino, Y. ; Grignani, G. ; Santini, D. ; Tonini, G. ; Vincenzi, B. / Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment. In: Scientific Reports. 2018 ; Vol. 8, No. 1.
@article{5cab37a154cf476f87261e6850f0186e,
title = "Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment",
abstract = "Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to standard treatments, therefore novel therapies are needed. c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. The present study aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ in in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signaling pathways. Furthermore, CBZ leads to the inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor κB (RANK), due to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.",
author = "M. Fioramonti and V. Fausti and F. Pantano and M. Iuliani and G. Ribelli and F. Lotti and Y. Pignochino and G. Grignani and D. Santini and G. Tonini and B. Vincenzi",
year = "2018",
month = "12",
day = "1",
doi = "10.1038/s41598-018-22469-5",
language = "English",
volume = "8",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Cabozantinib Affects Osteosarcoma Growth Through A Direct Effect On Tumor Cells and Modifications In Bone Microenvironment

AU - Fioramonti, M.

AU - Fausti, V.

AU - Pantano, F.

AU - Iuliani, M.

AU - Ribelli, G.

AU - Lotti, F.

AU - Pignochino, Y.

AU - Grignani, G.

AU - Santini, D.

AU - Tonini, G.

AU - Vincenzi, B.

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to standard treatments, therefore novel therapies are needed. c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. The present study aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ in in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signaling pathways. Furthermore, CBZ leads to the inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor κB (RANK), due to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.

AB - Osteosarcoma (OS) is the most common primary malignant tumor of the bone. Due to its high heterogeneity and to survival signals from bone microenvironment, OS can resist to standard treatments, therefore novel therapies are needed. c-MET oncogene, a tyrosine-kinase receptor, plays a crucial role in OS initiation and progression. The present study aimed to evaluate the effect of c-MET inhibitor cabozantinib (CBZ) on OS both directly and through its action on bone microenvironment. We tested different doses of CBZ in in vitro models of OS alone or in co-culture with bone cells in order to reproduce OS-tumor microenvironment interactions. CBZ is able to decrease proliferation and migration of OS cells, inhibiting ERK and AKT signaling pathways. Furthermore, CBZ leads to the inhibition of the proliferation of OS cells expressing receptor activator of nuclear factor κB (RANK), due to its effect on bone microenvironment, where it causes an overproduction of osteoprotegerin and a decrease of production of RANK ligand by osteoblasts. Overall, our data demonstrate that CBZ might represent a new potential treatment against OS, affecting both OS cells and their microenvironment. In this scenario, RANK expression in OS cells could represent a predictive factor of better response to CBZ treatment.

UR - http://www.scopus.com/inward/record.url?scp=85048288370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048288370&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-22469-5

DO - 10.1038/s41598-018-22469-5

M3 - Article

VL - 8

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 4177

ER -